Founded in 2006 and headquartered in Caesarea, Israel, IceCure Medical Ltd. is a commercial-stage medical device company specializing in the research, development, and marketing of cryoablation systems and technologies that use liquid nitrogen (LN2) to treat tumors. Their proprietary cryoablation technology offers a minimally invasive alternative to surgical intervention for tumor treatment, applicable to tumors found in the breast, lung, kidney, bone, and other clinical indications. Leading the industry with their advanced commercial cryoablation product, the ProSense system, IceCure Medical continues to innovate in minimally invasive oncology solutions. For more information, visit their website at http://www.icecure-medical.com. Company Address: 7 HaEshel St., PO Box 3163, Caesarea 3079504, Israel.